πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 429 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 8021687

Modified release compositions of milnacipran

Collegium Pharmaceutical, Inc. Β· Granted Tue Sep 20 2011 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 15 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8017763

Chemically modified oligonucleotides

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Sep 13 2011 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 08 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8017762

Modified iRNA agents

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Sep 13 2011 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 08 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8017149

Modified release preparations containing oxcarbazepine and derivatives thereof

Supernus Pharmaceuticals, Inc. Β· Granted Tue Sep 13 2011 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 08 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7988977

Modified live Aeromonas hydrophila vaccine for aquatic animals

The United States of America, as represented by the Secretary of Agriculture Β· Granted Tue Aug 02 2011 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 28 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7910131

Method of treating seizures using modified release formulations of oxcarbazepine

Supernus Pharmaceuticals, Inc. Β· Granted Tue Mar 22 2011 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 17 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7893224

Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Feb 22 2011 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 17 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7888070

Nucleic acids encoding growth hormone with a modified RSP sorting signal

The United States of America as Represented by the Secretary of the Department of Health and Human Services Β· Granted Tue Feb 15 2011 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 10 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7812132

Modified vitamin K-dependent polypeptides

Regents of the University of Minnesota Β· Granted Tue Oct 12 2010 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 07 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7807179

Modified reoviral therapy

The Board of Regents of the University of Texas System Β· Granted Tue Oct 05 2010 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 30 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7803385

Reoviruses having modified sequences

ONCOLYTICS BIOTECH INC. Β· Granted Tue Sep 28 2010 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 23 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7786133

Chemically modified small molecules

Nektar Therapeutics Β· Granted Tue Aug 31 2010 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 26 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7772387

Oligonucleotides comprising a modified or non-natural nucleobase

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Aug 10 2010 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 05 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7750120

Modified vitamin K-dependent polypeptides

Regents of the University of Minnesota Β· Granted Tue Jul 06 2010 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 01 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7745691

Genetically modified mouse lacking diacylglycerol acyltransferase-1 (DGAT-1) activity

The Regents of the University of California Β· Granted Tue Jun 29 2010 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 24 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7745608

Modified iRNA agents

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Jun 29 2010 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 24 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7722898

Modified-release preparations containing oxcarbazepine and derivatives thereof

Supernus Pharmaceuticals, Inc. Β· Granted Tue May 25 2010 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 20 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7704500

Methods of inhibiting ascites formation with modified chimeric VEGF polypeptides

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Apr 27 2010 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 22 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7704527

Modified release compositions of milnacipran

Collegium Pharmaceutical, Inc. Β· Granted Tue Apr 27 2010 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 22 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7674778

Oligonucleotides comprising a conjugate group linked through a C5-modified pyrimidine

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Mar 09 2010 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 04 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7662923

Modified vitamin K-dependent polypeptides

Regents of the University of Minnesota Β· Granted Tue Feb 16 2010 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 11 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7632932

Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Dec 15 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 10 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7632503

Method of treating a muscle-related condition with modified IGF1 polypeptides

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Dec 15 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 10 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7622105

Modified cytokines for use in cancer therapy

FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABOR Β· Granted Tue Nov 24 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 19 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted